Keros Therapeutics, Inc. (KROS)

60.57 +3.47 (+6.08%) At close: 04:00PM EDT

Keros Therapeutics, Inc.

1050 Waltham Street
Suite 302
Lexington, MA 02421
United States
617 314 6297
https://www.kerostx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 136

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jasbir S. Seehra Ph.D.	President, CEO & Director	1.13M	158.64k	1956
Mr. Keith C. Regnante MBA	Chief Financial Officer	636.11k	1.22M	1970
Mr. Christopher Rovaldi M.Sc.	Chief Operating Officer	784.9k	N/A	1975
Ms. Esther Cho J.D.	Senior VP, General Counsel & Secretary	N/A	N/A	N/A
Ms. Robin Wagner	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. John Oram M.B.A.	Senior Vice President of Program & Portfolio Management	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Corporate governance

Keros Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.